121 related articles for article (PubMed ID: 38014925)
1. Lysine demethylase 5B (KDM5B): A key regulator of cancer drug resistance.
Cao Y; Wu C; Ma L
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23587. PubMed ID: 38014925
[TBL] [Abstract][Full Text] [Related]
2. Lysine demethylase 5B (KDM5B): A potential anti-cancer drug target.
Zheng YC; Chang J; Wang LC; Ren HM; Pang JR; Liu HM
Eur J Med Chem; 2019 Jan; 161():131-140. PubMed ID: 30343192
[TBL] [Abstract][Full Text] [Related]
3. KDM5B demethylates H3K4 to recruit XRCC1 and promote chemoresistance.
Xu W; Zhou B; Zhao X; Zhu L; Xu J; Jiang Z; Chen D; Wei Q; Han M; Feng L; Wang S; Wang X; Zhou J; Jin H
Int J Biol Sci; 2018; 14(9):1122-1132. PubMed ID: 29989047
[TBL] [Abstract][Full Text] [Related]
4. Targeting histone demethylase KDM5B for cancer treatment.
Fu YD; Huang MJ; Guo JW; You YZ; Liu HM; Huang LH; Yu B
Eur J Med Chem; 2020 Dec; 208():112760. PubMed ID: 32883639
[TBL] [Abstract][Full Text] [Related]
5. KDM5B regulates the PTEN/PI3K/Akt pathway to increase sorafenib-resistance in hepatocellular carcinoma.
Liu J; Nie C
Anticancer Drugs; 2022 Oct; 33(9):840-849. PubMed ID: 35946516
[TBL] [Abstract][Full Text] [Related]
6. Histone demethylase lysine demethylase 5B in development and cancer.
Han M; Xu W; Cheng P; Jin H; Wang X
Oncotarget; 2017 Jan; 8(5):8980-8991. PubMed ID: 27974677
[TBL] [Abstract][Full Text] [Related]
7. SUMOylation negatively modulates target gene occupancy of the KDM5B, a histone lysine demethylase.
Bueno MT; Richard S
Epigenetics; 2013 Nov; 8(11):1162-75. PubMed ID: 23970103
[TBL] [Abstract][Full Text] [Related]
8. Histone demethylase KDM5B is a key regulator of genome stability.
Li X; Liu L; Yang S; Song N; Zhou X; Gao J; Yu N; Shan L; Wang Q; Liang J; Xuan C; Wang Y; Shang Y; Shi L
Proc Natl Acad Sci U S A; 2014 May; 111(19):7096-101. PubMed ID: 24778210
[TBL] [Abstract][Full Text] [Related]
9. Deubiquitinase USP7 stabilizes KDM5B and promotes tumor progression and cisplatin resistance in nasopharyngeal carcinoma through the ZBTB16/TOP2A axis.
Zhang B; Li J; Wang Y; Liu X; Yang X; Liao Z; Deng S; Deng Y; Zhou Z; Tian Y; Wei W; Meng J; Hu Y; Wan C; Zhang Z; Huang F; Wen L; Wu B; Sun Y; Li Y; Yang K
Cell Death Differ; 2024 Mar; 31(3):309-321. PubMed ID: 38287116
[TBL] [Abstract][Full Text] [Related]
10. KDM5B is a master regulator of the H3K4-methylome in stem cells, development and cancer.
Xhabija B; Kidder BL
Semin Cancer Biol; 2019 Aug; 57():79-85. PubMed ID: 30448242
[TBL] [Abstract][Full Text] [Related]
11. KDM5B histone demethylase controls epithelial-mesenchymal transition of cancer cells by regulating the expression of the microRNA-200 family.
Enkhbaatar Z; Terashima M; Oktyabri D; Tange S; Ishimura A; Yano S; Suzuki T
Cell Cycle; 2013 Jul; 12(13):2100-12. PubMed ID: 23759590
[TBL] [Abstract][Full Text] [Related]
12. Molecular architecture of the Jumonji C family histone demethylase KDM5B.
Dorosz J; Kristensen LH; Aduri NG; Mirza O; Lousen R; Bucciarelli S; Mehta V; Sellés-Baiget S; Solbak SMØ; Bach A; Mesa P; Hernandez PA; Montoya G; Nguyen TTTN; Rand KD; Boesen T; Gajhede M
Sci Rep; 2019 Mar; 9(1):4019. PubMed ID: 30858420
[TBL] [Abstract][Full Text] [Related]
13. The histone demethylase KDM5b/JARID1b plays a role in cell fate decisions by blocking terminal differentiation.
Dey BK; Stalker L; Schnerch A; Bhatia M; Taylor-Papidimitriou J; Wynder C
Mol Cell Biol; 2008 Sep; 28(17):5312-27. PubMed ID: 18591252
[TBL] [Abstract][Full Text] [Related]
14. KDM5B protein expressed in viable and fertile ΔARID mice exhibit no demethylase activity.
Jamshidi S; Catchpole S; Chen J; So CWE; Burchell J; Rahman KM; Taylor-Papadimitriou J
Int J Oncol; 2021 Nov; 59(5):. PubMed ID: 34713299
[TBL] [Abstract][Full Text] [Related]
15. Histone lysine demethylase KDM5B maintains chronic myeloid leukemia via multiple epigenetic actions.
Xue S; Lam YM; He Z; Zheng Y; Li L; Zhang Y; Li C; Mbadhi MN; Zheng L; Cheng Z; Liu Y; Wang X; Chan LC; Ng RK; Zhang J
Exp Hematol; 2020 Feb; 82():53-65. PubMed ID: 32007477
[TBL] [Abstract][Full Text] [Related]
16. Identification of the upstream regulators of KDM5B in gastric cancer.
Zhao LF; Qi FY; Zhang JG; Pang JR; Ren HM; Shen DD; Zhao LJ; Qi L; Liu HM; Zheng YC
Life Sci; 2022 Jun; 298():120458. PubMed ID: 35248525
[TBL] [Abstract][Full Text] [Related]
17. Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B).
Zhao B; Liang Q; Ren H; Zhang X; Wu Y; Zhang K; Ma LY; Zheng YC; Liu HM
Eur J Med Chem; 2020 Apr; 192():112161. PubMed ID: 32155529
[TBL] [Abstract][Full Text] [Related]
18. Discovery of an efficacious KDM5B PROTAC degrader GT-653 up-regulating IFN response genes in prostate cancer.
Guan T; Zhang Y; Li S; Zhang W; Song Y; Li Y; He Y; Chen Y
Eur J Med Chem; 2024 Jun; 272():116494. PubMed ID: 38749268
[TBL] [Abstract][Full Text] [Related]
19. CUX2/KDM5B/SOX17 Axis Affects the Occurrence and Development of Breast Cancer.
Li L; Zhu G; Tan K; Jiang L; Li Y; Zhu X; Lin Z; Zhang X; Chen J; Ma C
Endocrinology; 2022 Sep; 163(9):. PubMed ID: 35881915
[TBL] [Abstract][Full Text] [Related]
20. Aberrant KDM5B expression promotes aggressive breast cancer through MALAT1 overexpression and downregulation of hsa-miR-448.
Bamodu OA; Huang WC; Lee WH; Wu A; Wang LS; Hsiao M; Yeh CT; Chao TY
BMC Cancer; 2016 Feb; 16():160. PubMed ID: 26917489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
